Top

Published in:

01-03-2006 | Symposium in Writing

Thermal stress-related modulation of tumor cell physiology and immune responses

Author: Elfriede Noessner

Published in: Cancer Immunology, Immunotherapy | Issue 3/2006

Excerpt

The field of immunology has undergone a conceptual revolution during the past decade, which has helped us to better understand the connection between cancer and immunity. The characterization of tumor associated antigens and dendritic cell (DC) biology has spurred the development and clinical evaluation of immune therapies directed against cancer [1]. The demonstration that antitumor immune responses can be generated provides hope that cancer can be treated by modulating the immune system. …

Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296–306CrossRefPubMed

Hobohm U (2005) Fever therapy revisited. Br J Cancer 92:421–425PubMed

Nauts HC, McLaren JR (1990) Coley toxins—the first century. Adv Exp Med Biol 267:483–500PubMed

Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S, Marincola F (1999) Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126:112–120CrossRefPubMed

Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996). Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100–108PubMedCrossRef

Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A (1997) Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142–147CrossRefPubMed

Gao B, Tsan MF (2003) Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem 278:174–179CrossRefPubMed

Bausinger H, Lipsker D, Ziylan U, Manie S, Briand JP, Cazenave JP, Muller S, Haeuw JF, Ravanat C, de la Salle H, Hanau D (2002) Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol 32:3708–3713CrossRefPubMed

Osterloh A, Meier-Stiegen F, Veit A, Fleischer B, von Bonin A, Breloer M (2004) Lipopolysaccharide-free heat shock protein 60 activates T cells. J Biol Chem 279:47906–47911CrossRefPubMed

10.

Habich C, Kempe K, van der Zee R, Rumenapf R, Akiyama H, Kolb H, Burkart V (2005) Heat shock protein 60: specific binding of lipopolysaccharide. J Immunol 174:1298–1305PubMed

11.

Bausinger H, Lipsker D, Hanau D (2002) Heat-shock proteins as activators of the innate immune system. Trends Immunol 23:342–343CrossRefPubMed

12.

Reed RC, Berwin B, Baker JP, Nicchitta CV (2003) GRP94/gp96 elicits ERK activation in murine macrophages. A role for endotoxin contamination in NF-kappa B activation and nitric oxide production. J Biol Chem 278:31853–31860CrossRefPubMed

13.

Bandholtz L, Guo Y, Palmberg C, Mattsson K, Ohlsson B, High A, Shabanowitz J, Hunt DF, Jornvall H, Wigzell H, Agerberth B, Gudmundsson GH (2003) Hsp90 binds CpG oligonucleotides directly: implications for hsp90 as a missing link in CpG signaling and recognition. Cell Mol Life Sci 60:422–429CrossRefPubMed

14.

Triantafilou M, Triantafilou K (2002) Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 23:301–304CrossRefPubMed

15.

Prohaszka Z, Fust G (2004). Immunological aspects of heat-shock proteins—the optimum stress of life. Mol Immunol 41:29–44CrossRefPubMed

16.

Lumsden AB, Henderson JM, Kutner MH (1988) Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 8:232–236PubMedCrossRef

17.

Knolle PA, Germann T, Treichel U, Uhrig A, Schmitt E, Hegenbarth S, Lohse AW, Gerken G (1999) Endotoxin down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J Immunol 162:1401–1407PubMed

Title: Thermal stress-related modulation of tumor cell physiology and immune responses
Author: Elfriede Noessner
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 3/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-005-0038-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2006

Chaperone-rich cell lysates, immune activation and tumor vaccination

Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity

Dynamic control of lymphocyte trafficking by fever-range thermal stress

Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2

Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model

Effects of thermal stress on tumor antigenicity and recognition by immune effector cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer